Maria Toki
Maria Toki
Geverifieerd e-mailadres voor yale.edu
Geciteerd door
Geciteerd door
Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy
J Wang, J Sun, LN Liu, DB Flies, X Nie, M Toki, J Zhang, C Song, M Zarr, ...
Nature medicine 25 (4), 656-666, 2019
Expression analysis and significance of PD-1, LAG-3, and TIM-3 in human non–small cell lung cancer using spatially resolved and multiparametric single-cell analysis
I Datar, MF Sanmamed, J Wang, BS Henick, J Choi, T Badri, W Dong, ...
Clinical Cancer Research 25 (15), 4663-4673, 2019
A quantitative comparison of antibodies to programmed cell death 1 ligand 1
P Gaule, JW Smithy, M Toki, J Rehman, F Patell-Socha, D Cougot, ...
JAMA oncology 3 (2), 256-259, 2017
Spatially resolved and quantitative analysis of VISTA/PD-1H as a novel immunotherapy target in human non–small cell lung cancer
F Villarroel-Espindola, X Yu, I Datar, N Mani, M Sanmamed, V Velcheti, ...
Clinical Cancer Research 24 (7), 1562-1573, 2018
High-plex predictive marker discovery for melanoma immunotherapy–treated patients using digital spatial profiling
MI Toki, CR Merritt, PF Wong, JW Smithy, HM Kluger, KN Syrigos, GT Ong, ...
Clinical Cancer Research 25 (18), 5503-5512, 2019
Multiplex quantitative analysis of tumor-infiltrating lymphocytes and immunotherapy outcome in metastatic melanoma
PF Wong, W Wei, JW Smithy, B Acs, MI Toki, KRM Blenman, D Zelterman, ...
Clinical Cancer Research 25 (8), 2442-2449, 2019
Ki67 reproducibility using digital image analysis: an inter-platform and inter-operator study
B Acs, V Pelekanou, Y Bai, S Martinez-Morilla, M Toki, SCY Leung, ...
Laboratory Investigation 99 (1), 107-117, 2019
B7-H3 expression in NSCLC and its association with B7-H4, PD-L1 and tumor-infiltrating lymphocytes
M Altan, V Pelekanou, KA Schalper, M Toki, P Gaule, K Syrigos, ...
Clinical Cancer Research 23 (17), 5202-5209, 2017
Immune checkpoint inhibitor–associated pericarditis
M Altan, MI Toki, SN Gettinger, DE Carvajal-Hausdorf, J Zugazagoitia, ...
Journal of Thoracic Oncology 14 (6), 1102-1108, 2019
Immune marker profiling and programmed death ligand 1 expression across NSCLC mutations
MI Toki, N Mani, JW Smithy, Y Liu, M Altan, B Wasserman, R Tuktamyshov, ...
Journal of Thoracic Oncology 13 (12), 1884-1896, 2018
COVID-19 symptoms at hospital admission vary with age and sex: results from the ISARIC prospective multinational observational study
Infection 49 (5), 889-905, 2021
Oncogenic EGFR represses the TET1 DNA demethylase to induce silencing of tumor suppressors in cancer cells
M Forloni, R Gupta, A Nagarajan, LS Sun, Y Dong, V Pirazzoli, M Toki, ...
Cell reports 16 (2), 457-471, 2016
Quantitative assessment of CMTM6 in the tumor microenvironment and association with response to PD-1 pathway blockade in advanced-stage non–small cell lung cancer
J Zugazagoitia, Y Liu, M Toki, J McGuire, FS Ahmed, BS Henick, R Gupta, ...
Journal of Thoracic Oncology 14 (12), 2084-2096, 2019
Proof of the quantitative potential of immunofluorescence by mass spectrometry
MI Toki, F Cecchi, T Hembrough, KN Syrigos, DL Rimm
Laboratory Investigation 97 (3), 329-334, 2017
Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer
M Altan, KM Kidwell, V Pelekanou, DE Carvajal-Hausdorf, KA Schalper, ...
NPJ Breast Cancer 4 (1), 40, 2018
Biomarker discovery in patients with immunotherapy-treated melanoma with imaging mass cytometry
S Martinez-Morilla, F Villarroel-Espindola, PF Wong, MI Toki, TN Aung, ...
Clinical Cancer Research 27 (7), 1987-1996, 2021
ISARIC-COVID-19 dataset: a prospective, standardized, global dataset of patients hospitalized with COVID-19
M Etienne, N Ettalhaoui, AG Everding, M Evers, I Fabre, M Fabre, ...
Scientific data 9 (1), 454, 2022
The value of open-source clinical science in pandemic response: lessons from ISARIC
A Abbas, SA Abdukahil, NN Abdulkadir, R Abe, L Abel, L Absil, S Acharya, ...
The Lancet infectious diseases 21 (12), 1623-1624, 2021
The role of spread through air spaces (STAS) in lung adenocarcinoma prognosis and therapeutic decision making
MI Toki, K Harrington, KN Syrigos
Lung Cancer 146, 127-133, 2020
EGFR-GRB2 protein colocalization is a prognostic factor unrelated to overall EGFR expression or EGFR mutation in lung adenocarcinoma
MI Toki, DE Carvajal-Hausdorf, M Altan, J McLaughlin, B Henick, ...
Journal of Thoracic Oncology 11 (11), 1901-1911, 2016
Het systeem kan de bewerking nu niet uitvoeren. Probeer het later opnieuw.
Artikelen 1–20